Effect of supplementation in treatment of Coronary Heart Disease

Effects of folate supplementation on on carotid intima media thickness (CIMT) and metabolic profiles among type 2 diabetes patients with coronary heart disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201503175623N40

Enrollment

Registered

2015-03-28

Start date

2015-03-06

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease. Ischaemic heart disease (chronic) NOS

Interventions

Intervention 1: Intervention group: Folate tablet, 5 mg, daily, for 12 weeks orally. Intervention 2: Control group: Placebo tablet, daily, for 12 weeks orally.

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Subjects aged 40-85 years Diagnosed with type 2 diabetes and CVD

Exclusion criteria

Exclusion criteria: Intake of folate supplements within the last 3 months Acute myocardial infarction within the past 3 months Cardiac surgery within the past 3 months Renal or liver failure

Design outcomes

Primary

Measure	Time frame
Carotid intima media thickness. Timepoint: Baseline and End-of-trial. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;HDL-cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026